GLP-1 Safety and Monitoring: Questions for Your Visit

GLP-1 safety monitoring starts with the exact medicine, your health history and a plan for follow-up. Semaglutide, tirzepatide and other products have different indications and instructions. This guide helps you prepare questions; it does not choose a treatment, provide dosing directions or replace your prescriber's advice.

November 2026 update: sudden vision changes need prompt attention

On November 9, 2026, the FDA announced labeling changes about a potential increased risk of NAION, a rare eye condition that can cause permanent loss of vision. Sudden painless vision loss, new blind spots, distorted vision or changes in color perception warrant contacting a health professional right away. Do not wait for a routine follow-up appointment. Discuss concerns and treatment decisions with your clinician; this warning does not mean every person taking a GLP-1 medicine will develop the condition.

An earlier warning has also changed

In January 2026, the FDA requested removal of the suicidal behavior and ideation warning from affected GLP-1 weight-management products after its review found no increased risk. Earlier versions of this article described that evaluation as ongoing. Tell your health professional about new mood or behavior concerns, regardless of the cause.

What history should you bring?

Review the patient information for your exact prescription. For injectable semaglutide, MedlinePlus describes important precautions including a personal or family history of medullary thyroid carcinoma or MEN2. Bring a list of prescriptions, supplements, allergies, eye problems, digestive symptoms and previous pancreas or gallbladder problems. Discuss pregnancy or conception plans and any upcoming surgery or sedation with the relevant care team.

Which symptoms should you report?

Ask for a clear contact plan before starting. Nausea, vomiting, diarrhea or constipation can occur, but persistent or severe symptoms deserve medical advice. Severe continuing abdominal pain, difficulty breathing, significant swelling or other serious symptoms need urgent assessment. Tell the prescriber if vomiting or diarrhea makes it hard to keep fluids down. People taking insulin or certain other diabetes medicines should discuss low-blood-sugar risk and their individual response plan. This is not a complete list of possible side effects.

What will follow-up measure?

The NIDDK weight-management medication guide explains that suitability depends on health, other medicines, risks and costs. Ask when to return, which measurements or tests are useful and what would prompt reassessment. There is no universal laboratory schedule for every patient. Discuss tolerability, eating patterns, activity and meaningful health goals as well as scale weight; medicines do not replace nutrition and movement support.

Confirm the product and dispensing instructions

The FDA has reported problems with unapproved GLP-1 products, including dosing errors. Compounded medicines are not FDA approved. Confirm the product, pharmacy and instructions with your prescriber and pharmacist. Do not use an internet conversion chart to translate milligrams into syringe units, share medicines or change a dose yourself.

Bring these questions to your visit

• Why is this particular treatment being considered, and what alternatives fit my preferences?

• Which symptoms need an immediate call, and whom should I contact after hours?

• What should we monitor, when should we meet again and what would change the plan?

• What will the medicine, testing and follow-up cost separately?

At Atlanta Medical Institute, an in-person consultation in Sandy Springs is a starting point for that discussion. The $99 initial consultation is paid when booking; medicines, tests, procedures and follow-up cost extra. An evaluation does not guarantee a prescription. Call (404) 264-9553 with appointment questions.